CD59 and COVID-19: Interestingly, we found elevated CD55 (Figure 1C) but not CD59 (Figure 1D) monocyte surface expression levels in COVID-19 patients when compared to the control group, consistent with a compensatory mechanism in the setting of persistent complement activation.